Abstract
Similarities and differences in the epidemiology of cytomegalovirus (CMV), human herpesvirus 6 (HHV‐6) and human herpesvirus 7 (HHV‐7) infections are reviewed. Several distinct laboratory methods have been described for each virus. For CMV in immunocompromised patients, infection is best diagnosed by identifying active infection using routine surveillance cultures. Patients with active infection can then be entered into trials of suppressive therapy (where virus excretion is from the urine or saliva) or pre‐emptive therapy (where excretion is detected systemically). For HHV‐6 and HHV‐7, only anecdotal cases of associations with disease in immunocompromised patients have been reported. Recommendations cannot therefore be made about appropriate diagnostic strategies or about treatment since it is not clear if these viruses are pathogens or passengers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian Journal of Infectious Diseases and Medical Microbiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
